The New Rules of Excess Tens of millions of consumers are quietly changing shape. Build for who they are becoming.

Three waves are converging, and they are going to flatten every business built on food or beverage volume.

Someone who loses a third of their body weight does not just buy smaller clothes. They rebuild their entire week. Where they go, what they eat, who they see, what they drink. Multiply that by tens of millions and you are not looking at a pharma story. You are looking at a new consumer profile.

Health stopped being a deprivation and became a status. The people comparing recovery scores over coffee on Sunday are the same ones who used to be three drinks deep on a Thursday. It is the same crowd, spending the same social energy on the opposite thing.

Coke Zero didn't win because everyone suddenly stopped liking Coke. It removed one of the costs, and the third drink is starting to face the same calculation. Every number above is the same consumer asking: what does this give me, and what does it cost me?

Twenty years ago the hangover cost less, because there was less you were trying to protect, and nobody was measuring it. Now your wrist tells you before you reach for your morning coffee.

Diets fail. That is exactly why food and beverage survived every one of them. Atkins, keto, 5:2. The industry waited them out, because the customer always came back. This one doesn't fail.

And the science is compounding. Mounjaro made the category mainstream, while orforglipron removes another barrier: a pill, mass-manufacturable, without a needle or cold chain. Retatrutide goes further. In Phase 3, the highest dose produced 28.3% average weight loss over 80 weeks, and Lilly isn't alone. Competition across the category is accelerating.

Weight loss may eventually become only part of the proposition. Semaglutide has already demonstrated cardiovascular benefit, tirzepatide is approved for obstructive sleep apnea, and research continues across metabolic disease and other age-related conditions. The moment these drugs are increasingly prescribed not simply to make people thinner, but to keep them healthier for longer, the addressable consumer changes completely.

Weight loss is a market. Longevity is everyone.

Appetite may not be the end of it either. Randomised trials are now finding reductions in alcohol consumption and craving among people taking semaglutide, which potentially has enormous implications for hospitality. You don't necessarily decide to drink less. You simply want it less. The urge that used to fill the third and fourth round may simply become weaker.

Then there is adherence. The hard part of managing your health was never simply knowing what to do. It was the admin: what should I eat, how much protein do I need, what should I order, why has my weight stalled, what do these numbers mean? That used to require a nutritionist, a trainer and a level of discipline most people don't have. Increasingly, you can ask a machine. Photograph the plate, read the label, interpret the bloodwork, adjust dinner.

Weight management traditionally broke at two points: appetite and adherence. The drug attacks appetite. AI attacks adherence. Both are being engineered out at the same time.

Which is why being at a healthy weight increasingly stops being an achievement and starts becoming a baseline. Once people invest this much effort, technology and money into their health, they become much less casual about trading it away.

Every operator in this region tells me they have time.

The argument goes: 11% is an American number. My crowd is not on Mounjaro. Wegovy is expensive here and niche. This is a US panic on a five year delay, and I will adapt when it actually lands.

It doesn't work like that, and the reason is sitting in their hand.

Millions of people are now getting visible results, and people with visible results make content: transformations, macros, training splits, what I eat in a day, sober Sundays, recovery scores, Pilates, Hyrox, protein everything. More content means more chances for it to land in front of people who have never taken a GLP-1 and never will. They copy the behaviour without the prescription.

A lot of that behaviour looks the same whether the trigger is a GLP-1 or simply trying to lose fat: more protein, fewer calories, less alcohol, more planning. That means several trends are compounding at once and moving consumers in roughly the same direction regardless of actual drug adoption.

Vanity is doing more work here than health ever did, and vanity does not plateau.

Southeast Asia is one of the most social media saturated regions on earth. The behaviour arrives through the phone years before the prescription arrives through the health authority.

That is what makes this tidal rather than cyclical. One trend you can wait out. A demand shift, a drug pipeline and a content engine that feeds both of them do not recede.

Do not size this market by the number of people on the drug. Size it by the number of people who now want to live an aesthetic and healthy lifestyle.

Champagne trains. Tables stacked with shared dishes at supper. Free flow.

Thirty years of hospitality promotion has been a variation on the word more, and more is what this customer is becoming more selective about.

They still indulge, but indulgence has become a line item: a cheat day, a birthday, a deal closed. Planned, budgeted and earned against a week of deficits, because there is a daily number to hit and everything either side of the blowout is a subtraction.

What gets squeezed first is everything unplanned. The after-work pint. The third round nobody wanted. The extra round because nobody wanted to be the first to leave. The drink you had because you were standing there.

A birthday table outspends a Tuesday ten to one. But there are only so many birthdays, and there used to be a lot of Tuesdays.

People still go big. They're just more discerning about the occasion.

A Hyrox race in Bangkok with a refeed food tour booked for the day after. A State of Trance in Vietnam. A wedding in Bali, then a few days of beach clubs and recovery clubs in Uluwatu. Calories, money and recovery all spent in one hit, and nobody burns all three on something merely fine. Over the top, or bed by ten.

For most of modern life, the bar wasn't really about the drink. It was where you went to meet someone, find your people, flirt, celebrate, or just be out in the world. Alcohol helped organize the occasion, but the underlying demand was social.

Two new Singapore openings show what happens when you build around that demand differently.

Foura puts Blue Zone-inspired food alongside breathwork, run clubs, Pilates and sound baths, with an explicit ambition to become somewhere people return for shared rituals.

Madison House comes at it from the other end of the market: 37,000 square feet across padel, pools, Technogym, longevity, recovery and hospitality. There is a bar, but it is one part of a much bigger reason to be there.

Different models, same shift. The drink is becoming one part of the occasion rather than the whole reason for it.